AbbVie announced positive topline data from a phase 3 study evaluating the efficacy and safety of risankizumab (Skyrizi) compared with secukinumab (Cosentyx; Novartis) in adult patients with moderate to severe plaque psoriasis.
Recalcitrant lesions on the anterior lower legs resolved by changing the injection site from the abdomen to the lower legs.
In a novel head-to-head study comparing guselkumab and ustekinumab in both biologic-naive and experienced patients, guselkumab demonstrated a significantly higher probability of achieving and maintaining PASI treatment response through week 40 compared with ustekinumab.
Treatment scenarios with tildrakizumab, such as long-term continuous dosing (upto 64 weeks), treatment interruption/reinitiation, and switching from another biologic,can be part of the management of plaque psoriasis with a reasonable expectationof efficacy and tolerability.
Patients with psoriasis who were prescribed ixekizumab demonstrated longer drug persistence, lower discontinuation rate and lower risk for discontinuation, higher likelihood of adherence, and similar risk for switching compared with patients prescribed secukinumab.
IL-17 and IL-23 inhibitors appear to be well tolerated, with good safety profiles; recent findings outlined here may aid clinical decision making when choosing the most appropriate therapy for patients with moderate to severe psoriasis.
Rates of type 2 diabetes may be higher among patients with psoriasis.
Machine learning methods identified top predictors of coronary artery burden in patients with psoriasis, which were markers related to obesity, dyslipidemia, and inflammation, demonstrating that these are potentially important comorbidities to treat in psoriasis.
A new guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations for treating pediatric patients with psoriasis.
The first study to compare the real-world survival of a single biologic administered in-office with the same agent administered at home suggests that in-office ustekinumab administration may result in superior drug survival.